Scarica l'app Stockscreener
3.17
1.25%
-0.04
Dopo l'orario di chiusura:
3.16
-0.010
-0.32%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.21
Aprire:
$3.14
Volume 24 ore:
1.35M
Relative Volume:
1.48
Capitalizzazione di mercato:
$213.53M
Reddito:
$488.00K
Utile/perdita netta:
$-41.44M
Rapporto P/E:
-3.4086
EPS:
-0.93
Flusso di cassa netto:
$-31.47M
1 W Prestazione:
+12.81%
1M Prestazione:
+35.47%
6M Prestazione:
-19.54%
1 anno Prestazione:
-18.82%
Intervallo 1D:
$3.1013
$3.30
Intervallo di 1 settimana:
$2.6111
$3.30
Portata 52W:
$1.90
$4.99
Cardiff Oncology Inc Stock (CRDF) Company Profile
Nome
Cardiff Oncology Inc
Settore
Industria
Telefono
858-952-7570
Indirizzo
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Confronta CRDF con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
3.17 | 216.23M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Iniziato | Noble Capital Markets | Outperform |
| 2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2025-06-24 | Iniziato | Jefferies | Hold |
| 2024-09-06 | Iniziato | Craig Hallum | Buy |
| 2022-01-05 | Iniziato | William Blair | Outperform |
| 2021-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2021-08-09 | Ripresa | Maxim Group | Buy |
| 2020-10-22 | Iniziato | H.C. Wainwright | Buy |
| 2020-10-08 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Cardiff Oncology Inc Borsa (CRDF) Ultime notizie
Is Cardiff Oncology Inc. stock a buy for dividend growthJuly 2025 Action & Long Hold Capital Preservation Tips - ulpravda.ru
Aug Wrap: How Cardiff Oncology Inc XE7C stock reacts to Fed tightening2025 Breakouts & Breakdowns & Fast Gain Stock Tips - moha.gov.vn
How Cardiff Oncology Inc. (XE7C) stock reacts to Fed tighteningRisk Management & Stepwise Swing Trade Plans - ulpravda.ru
Equities Analysts Issue Forecasts for CRDF Q4 Earnings - Defense World
Can Cardiff Oncology Inc. stock double in next 5 yearsDividend Growth Stocks & Today’s Picks, Tomorrow’s Winners - ulpravda.ru
What is Noble Financial’s Estimate for CRDF FY2025 Earnings? - Defense World
Analysts Offer Predictions for CRDF FY2025 Earnings - MarketBeat
Cardiff Oncology stock initiated with Outperform rating by Noble Capital - Investing.com Australia
Noble Financial Initiates Coverage on Cardiff Oncology (NASDAQ:CRDF) - MarketBeat
Cardiff Oncology Inc. (CRDF) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Investors Purchase High Volume of Call Options on Cardiff Oncology (NASDAQ:CRDF) - Defense World
Cardiff Oncology (FRA:XE7C) EV-to-OCF : -3.04 (As of Dec. 24, 2025) - GuruFocus
Stock Traders Purchase High Volume of Cardiff Oncology Call Options (NASDAQ:CRDF) - MarketBeat
Flputnam Investment Management Co. Purchases 543,370 Shares of Cardiff Oncology, Inc. $CRDF - MarketBeat
Why analysts raise outlook for Cardiff Oncology Inc. (XE7C) stockTrade Analysis Report & Precise Swing Trade Entry Alerts - Улправда
3 Penny Stocks With At Least $100M Market Cap - simplywall.st
Short Covering: How analysts revise price targets for ConAgra Brands Inc stockPrice Action & Low Risk Profit Maximizing Plans - moha.gov.vn
Cardiff Oncology Earnings Notes - Trefis
Will Cardiff Oncology Inc. stock benefit from green energy trendsQuarterly Portfolio Summary & Verified Technical Trade Signals - Улправда
Quarterly Earnings: Will SIFYR stock continue dividend increasesMarket Activity Summary & AI Forecasted Entry and Exit Points - moha.gov.vn
Is Cardiff Oncology Inc. stock affected by interest rate hikesWeekly Profit Summary & Weekly Breakout Watchlists - Улправда
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $10.83 Average Price Target from Analysts - Defense World
Published on: 2025-12-20 05:10:29 - Улправда
Institution Moves: Will Cardiff Oncology Inc. stock benefit from green energy trendsCPI Data & Daily Profit Focused Screening - Улправда
Aug Spikes: Is Cardiff Oncology Inc. stock affected by interest rate hikes2025 Retail Activity & Safe Swing Trade Setup Alerts - Улправда
Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates - sharewise.com
Cardiff Oncology (STU:XE7C) EV-to-FCF : -2.30 (As of Dec. 18, 2025) - GuruFocus
Can Cardiff Oncology Inc. stock sustain revenue growthJuly 2025 Momentum & Consistent Return Investment Signals - Улправда
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Rating of "Hold" by Brokerages - MarketBeat
Operating cash flow per share of Cardiff Oncology, Inc. – LSX:A2P4GU - TradingView — Track All Markets
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era - The Manila Times
Zacks Small Cap Weighs in on CRDF FY2025 Earnings - Defense World
What drives Cardiff Oncology Inc stock priceSmall Cap Stock Opportunities & Free Daily Stock Hotspot Analysis - earlytimes.in
Cardiff Oncology CRDF US - Smartkarma
FY2025 Earnings Forecast for CRDF Issued By Zacks Small Cap - MarketBeat
A new trading data show Cardiff Oncology Inc (CRDF) is showing positive returns. - setenews.com
Institutions profited after Cardiff Oncology, Inc.'s (NASDAQ:CRDF) market cap rose US$19m last week but retail investors profited the most - Yahoo Finance
CRDF: Initiating Coverage – Combination Therapy Elicits Superior Response - Zacks Small Cap Research
Cardiff Presents Phase 1 Data Of Onvensertib In Chronic Myelomonocytic Leukemia At ASH 2025 - Nasdaq
Cardiff oncology reports positive results for onvansertib in leukemia trial - Investing.com
Cardiff oncology reports positive results for onvansertib in leukemia trial By Investing.com - Investing.com India
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025 - The Manila Times
Cardiff Oncology Announces Clinical Data from - One News Page
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference - The Manila Times
Is Cardiff Oncology Inc. stock a contrarian buy2025 Key Highlights & Technical Pattern Based Signals - Newser
How Cardiff Oncology Inc. (XE7C) stock stacks up against competitorsMarket Risk Report & Low Volatility Stock Recommendations - Newser
Will Cardiff Oncology Inc. (XE7C) stock announce a stock splitAnalyst Upgrade & Technical Pattern Based Signals - Newser
Cardiff Oncology Inc Azioni (CRDF) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):